Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
$6.37
$0.38
$1.24
$26.05M0.91522,308 shs466,373 shs
CTYX
Curative Biotechnology
$0.01
-14.4%
$0.01
$0.00
$0.22
$55.95M-33.993.01 million shs1.04 million shs
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.01
-0.7%
$0.01
$0.00
$0.10
$881K7.5524,338 shs500 shs
GRNV
GreenVision Acquisition
$10.89
$7.70
$25.30
$37K0.07105,738 shs1.54 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00%0.00%0.00%0.00%0.00%
CTYX
Curative Biotechnology
-3.06%-3.06%-14.57%-36.67%-50.00%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00%-8.00%-12.77%-18.82%-84.89%
GRNV
GreenVision Acquisition
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.5153 of 5 stars
0.02.00.00.02.81.70.0
GRNV
GreenVision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00
N/AN/AN/A
CTYX
Curative Biotechnology
0.00
N/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00
N/AN/AN/A
GRNV
GreenVision Acquisition
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/A$1.54 per shareN/A
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$16.65M0.05N/AN/A($0.88) per share-0.02
GRNV
GreenVision Acquisition
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/A
CTYX
Curative Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-$6.45M-$0.11N/AN/A-26.79%N/A-17.85%N/A
GRNV
GreenVision Acquisition
-$510KN/A0.00N/AN/AN/A-54.82%-2.65%N/A

Latest GRNV, EMMA, CTYX, and CLBS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A-$0.04N/A-$0.04N/AN/A
4/14/2025Q4 2024
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A-$0.03N/A-$0.03N/A$3.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/A
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/A
GRNV
GreenVision Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/A
22.33
22.33
CTYX
Curative Biotechnology
N/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A
0.09
0.06
GRNV
GreenVision Acquisition
N/A
0.29
0.29
CompanyEmployeesShares OutstandingFree FloatOptionable
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2760.58 million59.25 millionOptionable
CTYX
Curative Biotechnology
4388.50 millionN/ANot Optionable
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
6063.87 million41.51 millionNot Optionable
GRNV
GreenVision Acquisition
N/A3.35 millionN/ANot Optionable

Media Sentiment Over Time

Caladrius Biosciences stock logo

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Curative Biotechnology OTCMKTS:CTYX

$0.0095 0.00 (-14.41%)
As of 07/3/2025

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.

Emmaus Life Sciences stock logo

Emmaus Life Sciences OTCMKTS:EMMA

$0.01 0.00 (-0.72%)
As of 07/3/2025 11:51 AM Eastern

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

GreenVision Acquisition NASDAQ:GRNV

As of April 1, 2021, operates as a subsidiary of Helbiz, Inc..